Shennon Biotechnologies

Executive Summary

Shennon Biotechnologies is a San Diego-based private biotech company pioneering a unique platform that profiles millions of cell-cell interactions at single-cell resolution to identify novel therapeutic targets for cancer and autoimmune diseases. By combining ultra-fast single-cell interaction mapping with proprietary artificial intelligence models, the company aims to discover and develop more effective and safer drugs. Founded in 2018, Shennon operates at the forefront of cell and gene therapy, leveraging its functional response screening to decode complex cellular communication networks. While the company remains in early stages with no disclosed funding rounds or pipeline candidates, its technology holds promise for transforming target identification in immuno-oncology and autoimmune indications. The lack of public data suggests a need for upcoming value-driven milestones to validate its platform.

Upcoming Catalysts (preview)

• Q1 2027Series A Funding Announcement60% success
• Q4 2026Peer-Reviewed Publication Demonstrating Platform Validation50% success
• Q2 2027First Therapeutic Candidate Nomination40% success